Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Diluted Average) (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $63.0 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 14.72% year-over-year to $63.0 million; the TTM value through Dec 2025 reached $63.0 million, up 14.72%, while the annual FY2025 figure was $63.0 million, 14.72% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $63.0 million in Q4 2025 per FHTX's latest filing, roughly flat from $63.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $63.0 million in Q3 2025 and bottomed at $36.8 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $47.0 million, with a median of $41.9 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 597.01% in 2021, then grew 0.68% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $37.2 million in 2021, then increased by 11.89% to $41.6 million in 2022, then grew by 0.92% to $42.0 million in 2023, then surged by 30.79% to $54.9 million in 2024, then increased by 14.72% to $63.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $63.0 million in Q4 2025, $63.0 million in Q3 2025, and $62.9 million in Q2 2025.